We further observed that sensitivity to Bcl-2 inhibitors (venetoclax and sonrotoclax), both as single agents and in combinations, was reduced in CLL cells from idelalisib-resistant/intolerant patients compared to CLL cells from treatment naïve patients (Fig. 4a, left, and Supplementary Fig. 5b). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.